Frontiers in Medicine (Apr 2022)
Medication Non-adherence and Condomless Anal Intercourse Increased Substantially During the COVID-19 Pandemic Among MSM PrEP Users: A Retrospective Cohort Study in Four Chinese Metropolises
- Yangyang Gao,
- Yangyang Gao,
- Yangyang Gao,
- Yangyang Gao,
- Qinghai Hu,
- Qinghai Hu,
- Qinghai Hu,
- Qinghai Hu,
- Sequoia I. Leuba,
- Le Jia,
- Le Jia,
- Le Jia,
- Le Jia,
- Hongyi Wang,
- Hongyi Wang,
- Hongyi Wang,
- Hongyi Wang,
- Xiaojie Huang,
- Yaokai Chen,
- Hui Wang,
- Jing Zhang,
- Jing Zhang,
- Jing Zhang,
- Jing Zhang,
- Zhenxing Chu,
- Zhenxing Chu,
- Zhenxing Chu,
- Zhenxing Chu,
- Lukun Zhang,
- Zixin Wang,
- Hong Shang,
- Hong Shang,
- Hong Shang,
- Hong Shang,
- Junjie Xu,
- Junjie Xu,
- Junjie Xu,
- Junjie Xu,
- CROPrEP Study Team,
- Xiaoqing He,
- Yao Li,
- Fang Zhao,
- Yijun Duan,
- Rui Li,
- Shangcao Li,
- Hang Li,
- Zhili Hu,
- Rantong Bao,
- Sitong Cui,
- Zhaozhen Liu,
- Zehao Ye,
- Xiaoyun Shi
Affiliations
- Yangyang Gao
- National Health Commission Key Laboratory of Acquired Immunodeficiency Syndrome (AIDS) Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China
- Yangyang Gao
- Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang, China
- Yangyang Gao
- Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China
- Yangyang Gao
- Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China
- Qinghai Hu
- National Health Commission Key Laboratory of Acquired Immunodeficiency Syndrome (AIDS) Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China
- Qinghai Hu
- Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang, China
- Qinghai Hu
- Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China
- Qinghai Hu
- Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China
- Sequoia I. Leuba
- Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
- Le Jia
- National Health Commission Key Laboratory of Acquired Immunodeficiency Syndrome (AIDS) Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China
- Le Jia
- Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang, China
- Le Jia
- Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China
- Le Jia
- Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China
- Hongyi Wang
- National Health Commission Key Laboratory of Acquired Immunodeficiency Syndrome (AIDS) Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China
- Hongyi Wang
- Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang, China
- Hongyi Wang
- Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China
- Hongyi Wang
- Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China
- Xiaojie Huang
- Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China
- Yaokai Chen
- Chongqing Public Health Medical Center, Chongqing, China
- Hui Wang
- Department of Infectious Diseases, National Clinical Center for Infectious Diseases, Third People's Hospital of Shenzhen, Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China
- Jing Zhang
- National Health Commission Key Laboratory of Acquired Immunodeficiency Syndrome (AIDS) Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China
- Jing Zhang
- Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang, China
- Jing Zhang
- Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China
- Jing Zhang
- Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China
- Zhenxing Chu
- National Health Commission Key Laboratory of Acquired Immunodeficiency Syndrome (AIDS) Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China
- Zhenxing Chu
- Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang, China
- Zhenxing Chu
- Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China
- Zhenxing Chu
- Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China
- Lukun Zhang
- Department of Infectious Diseases, National Clinical Center for Infectious Diseases, Third People's Hospital of Shenzhen, Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China
- Zixin Wang
- Faculty of Medicine, The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China
- Hong Shang
- National Health Commission Key Laboratory of Acquired Immunodeficiency Syndrome (AIDS) Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China
- Hong Shang
- Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang, China
- Hong Shang
- Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China
- Hong Shang
- Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China
- Junjie Xu
- National Health Commission Key Laboratory of Acquired Immunodeficiency Syndrome (AIDS) Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China
- Junjie Xu
- Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang, China
- Junjie Xu
- Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China
- Junjie Xu
- Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China
- CROPrEP Study Team
- Xiaoqing He
- Yao Li
- Fang Zhao
- Yijun Duan
- Rui Li
- Shangcao Li
- Hang Li
- Zhili Hu
- Rantong Bao
- Sitong Cui
- Zhaozhen Liu
- Zehao Ye
- Xiaoyun Shi
- DOI
- https://doi.org/10.3389/fmed.2022.738541
- Journal volume & issue
-
Vol. 9
Abstract
BackgroundThe coronavirus disease (COVID-19) pandemic has impacted HIV prevention strategies globally. However, changes in pre-exposure prophylaxis (PrEP) adherence and HIV-related behaviors, and their associations with medication adherence among men who have sex with men (MSM) PrEP users remain unclear since the onset of the COVID-19 pandemic.MethodsA Retrospective Cohort Study of HIV-negative MSM PrEP users was conducted in four Chinese metropolises from December 2018 to March 2020, assessing the changes in PrEP adherence and HIV-related behaviors before and during the COVID-19. The primary outcome was poor PrEP adherence determined from self-reported missing at least one PrEP dose in the previous month. We used multivariable logistic regression to determine factors correlated with poor adherence during COVID-19.ResultsWe enrolled 791 eligible participants (418 [52.8%] in daily PrEP and 373 [47.2%] in event-driven PrEP). Compared with the data conducted before the COVID-19, the proportion of PrEP users decreased from 97.9 to 64.3%, and the proportion of poor PrEP adherence increased from 23.6 to 50.1% during the COVID-19 [odds ratio (OR) 3.24, 95% confidence interval (CI) 2.62–4.02]. While the percentage of condomless anal intercourse (CAI) with regular partners (11.8 vs. 25.7%) and with casual partners (4.4 vs. 9.0%) both significantly increased. The proportion of those who were tested for HIV decreased from 50.1 to 25.9%. Factors correlated with poor PrEP adherence during the COVID-19 included not being tested for HIV (adjusted odds ratio [aOR] = 1.38 [95% CI: 1.00, 1.91]), using condoms consistently with regular partners (vs. never, aOR = 2.19 [95% CI: 1.16, 4.13]), and being married or cohabitating with a woman (vs. not married, aOR = 3.08 [95% CI: 1.60, 5.95]).ConclusionsIncreased poor PrEP adherence and CAI along with the decrease in HIV testing can lead to an increase in HIV acquisition and drug resistance to PrEP. Targeted interventions are needed to improve PrEP adherence and HIV prevention strategies.
Keywords
- COVID-19
- pre-exposure prophylaxis (PrEP)
- adherence–compliance–persistence
- men who have sex with men (MSM)
- condomless anal intercourse (CAI)